SIRT1 and polycystic ovary syndrome: Sodium glucose co transporter‐2 inhibitors (SGLT‐2i); empagliflozin combined to metformin could enhance hormonal parameters, insulin resistance, and inflammatory biomarkers in rat model of PCOS‐IR with modulating ovarian AMPK‐SIRT1 pathway which may be the molecular basis for IR in PCOS and may potentially be a therapeutic target.